THE HEART OF THE MATTER

Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The company is focused on the development of minimally-invasive treatments for two of the most vexing challenges in cardiology today; refractory angina and mitral regurgitation. We believe there is tremendous potential in addressing these hard-to-treat conditions.

Neovasc is a publicly-traded company on both the NASDAQ and Toronto stock exchanges.

 

NVCN

NASDAQ

TORONTO (TSX)

CORPORATE
PRESENTATION

May 2, 2022

download here (pdf) >

NEOVASC Q1 Earnings Call
Thursday, May 12, 2022 at 4:30 p.m. ET

Webcast: register here
Conference call by dialing (877) 407-9208 or
(201) 493-6784 (International)
and reference Conference ID 13729200